scanX
Granules

Granules

544.20
-6.60
(-1.20%)
hide
Key Fundamentals
Add Ratio
Market Cap
13,206.03 Cr
EPS
20.69
PE Ratio
26.06
Dividend Yield
0.27 %
Industry
Healthcare
52 Week High
628.00
52 Week Low
422.00
PB Ratio
3.35
Debt to Equity
0.40
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Granules India Reports 34% Revenue Growth in Q2 FY26, FDA Meeting Scheduled for January 20264 days ago
Granules India achieved quarterly revenues of Rs. 12,970 million with 34% year-on-year growth and 65.7% gross margin, driven by formulations business in North America and Europe. The company secured FDA meeting for January 2026 regarding Gagillapur facility remediation and received first FDA approval for its Genome Valley facility, while Ascelis Peptides reported Rs. 200 million EBITDA loss.
neutral
Granules India Reports 34% Revenue Growth in Q2FY26 with Strong Performance in North America and Europe9 days ago
Granules India achieved revenue of ₹12,970 Mn in Q2FY26, marking 34% year-over-year growth driven by formulations business in North America and Europe, with EBITDA rising 37% to ₹2,782 Mn despite ₹200 Mn loss from Ascelis Peptides. The pharmaceutical company received 91 US FDA approvals to date, filed 3 ANDAs during the quarter, and maintained strong cash flow from operations at ₹1,937 Mn while investing ₹2,112 Mn in capex for expansion.
neutral
Granules India Appoints New CHRO as Atul Dhavle Resigns10 days ago
Granules India Limited announced leadership changes in its senior management. Vinodkumar Parur has been appointed as Chief Human Resources Officer (CHRO) effective November 17, 2025, and designated as Senior Management Personnel. Parur brings over 24 years of HR leadership experience across manufacturing, engineering, pharmaceuticals and infrastructure sectors, with previous senior roles at RR Kabel Limited and Nilkamal Limited. He holds a master's degree in management studies from PIMSR, Mumbai University. Meanwhile, Atul Dhavle will cease to be Senior Management Personnel effective November 16, 2025, following his resignation from the CHRO position to explore other opportunities. Dhavle will serve a notice period for transition purposes.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,779.70
#1 4,27,009.64
40.68
#1 54,729.00
9.71
#1 10,980
2.89
71.91
Divis Laboratories
6,373.00
1,69,183.13
69.05
9,712.00
18.67
2,191
35.10
42.53
Torrent Pharmaceuticals
3,686.50
1,24,767.91
58.80
11,539.40
6.99
1,911
30.46
50.58
Cipla
1,511.80
1,22,116.26
22.73
28,409.50
7.12
5,291
3.71
43.38
Dr Reddys Laboratories
1,243.90
1,03,817.61
#1 18.15
33,741.20
16.73
5,725
-0.38
51.48
Zydus Life Science
924.30
93,006.20
18.56
23,511.00
18.55
4,615
34.60
32.09
Lupin
2,029.40
92,693.76
21.34
22,909.50
13.74
3,306
#1 72.75
58.39
Mankind Pharma
2,242.10
92,544.58
52.05
12,744.20
#1 20.90
2,007
-21.05
33.57
Aurobindo Pharma
1,205.90
70,038.87
20.70
32,345.60
9.43
3,484
3.81
62.63
Alkem Laboratories
5,700.00
68,152.00
28.29
13,458.30
3.70
2,216
10.98
60.35
Growth Rate
Revenue Growth
-0.36 %
Net Income Growth
23.74 %
Cash Flow Change
97.21 %
ROE
7.40 %
ROCE
-5.42 %
EBITDA Margin (Avg.)
11.80 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
357
324
354
326
372
347
362
357
356
382
404
417
517
483
598
640
634
623
708
708
682
741
861
861
803
858
893
1,002
1,034
1,024
1,156
1,147
1,199
984
1,190
1,150
1,171
1,171
960
1,139
1,230
1,225
1,294
Expenses
306
260
284
260
292
275
284
277
278
302
316
337
460
381
480
519
516
477
556
573
500
552
602
633
597
648
737
823
837
808
908
915
967
849
977
905
920
921
763
907
945
989
1,019
EBITDA
51
64
69
67
81
72
78
81
79
80
89
80
57
102
118
121
119
146
152
135
182
189
260
228
205
209
156
179
197
216
248
232
232
135
213
245
251
251
197
232
284
236
275
Operating Profit %
14 %
19 %
19 %
20 %
21 %
20 %
21 %
22 %
22 %
20 %
20 %
18 %
9 %
16 %
17 %
18 %
16 %
20 %
21 %
19 %
17 %
25 %
30 %
25 %
25 %
24 %
17 %
17 %
19 %
21 %
21 %
20 %
19 %
14 %
18 %
21 %
21 %
21 %
20 %
20 %
21 %
18 %
21 %
Depreciation
14
14
14
15
15
16
19
19
18
18
19
20
20
25
27
27
27
29
30
39
39
34
36
37
45
39
40
39
40
43
44
48
49
49
53
52
53
53
53
57
64
69
72
Interest
8
8
9
10
9
8
8
8
8
8
10
8
6
7
8
8
7
7
7
7
7
6
6
7
7
7
6
5
6
7
13
17
19
23
26
29
29
27
26
27
24
24
29
Profit Before Tax
29
42
46
42
56
47
51
54
53
55
60
52
30
71
84
87
84
110
115
89
137
149
217
184
154
163
110
135
150
166
190
167
164
66
136
170
176
181
128
153
198
145
176
Tax
7
14
14
13
23
8
11
15
7
18
19
17
10
19
23
27
20
27
19
25
44
38
54
37
26
43
30
34
39
38
45
43
44
18
34
45
46
47
31
35
46
32
45
Net Profit
22
29
32
29
33
39
41
39
46
37
40
35
20
52
60
60
64
83
96
64
92
111
164
147
128
120
81
101
111
128
145
124
120
48
102
126
130
135
97
118
152
113
131
EPS in ₹
1.10
1.40
1.58
1.42
1.60
1.80
1.88
1.79
2.09
1.61
1.76
1.38
0.81
2.04
2.37
2.37
2.52
3.27
3.77
2.52
3.63
4.39
6.60
5.92
5.15
4.85
3.26
4.07
4.48
5.14
5.85
5.11
4.94
1.98
4.22
5.18
5.35
5.56
4.01
4.85
6.27
4.64
5.38
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,203
1,563
1,879
2,677
2,983
3,228
3,714
4,513
4,905
5,521
6,253
Fixed Assets
617
560
644
777
944
1,204
1,332
1,541
1,911
2,096
2,427
Current Assets
500
818
828
1,187
1,282
1,629
1,997
2,505
2,574
2,905
3,116
Capital Work in Progress
62
77
267
515
496
294
239
356
239
272
440
Investments
0
70
108
157
210
19
19
20
21
22
22
Other Assets
524
856
859
1,229
1,332
1,711
2,123
2,596
2,733
3,132
3,364
Total Liabilities
1,203
1,563
1,879
2,677
2,983
3,228
3,714
4,513
4,905
5,521
6,253
Current Liabilities
415
655
787
878
897
893
1,173
1,642
1,814
2,082
2,003
Non Current Liabilities
357
247
188
495
557
491
367
284
256
213
534
Total Equity
431
662
904
1,304
1,530
1,844
2,173
2,587
2,835
3,226
3,716
Reserve & Surplus
411
613
881
1,279
1,504
1,818
2,149
2,562
2,811
3,201
3,691
Share Capital
20
22
23
25
25
25
25
25
24
24
24
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
24
75
-82
66
-25
103
-144
143
107
90
85
Investing Activities
-146
-162
-326
-462
-270
-160
-277
-379
-192
-358
-689
Operating Activities
150
151
188
-1
262
476
433
332
739
439
867
Financing Activities
19
86
56
529
-17
-213
-299
190
-440
8
-93
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
42.04 %
42.04 %
42.04 %
41.98 %
41.98 %
41.98 %
41.93 %
42.02 %
42.02 %
42.02 %
42.02 %
41.96 %
41.96 %
41.96 %
38.87 %
38.87 %
38.85 %
38.84 %
38.82 %
38.82 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
19.57 %
20.39 %
19.49 %
15.87 %
15.15 %
0.00 %
14.09 %
DIIs
1.50 %
2.86 %
2.77 %
4.34 %
3.97 %
3.03 %
4.32 %
4.23 %
4.76 %
5.03 %
6.68 %
6.85 %
10.14 %
10.70 %
14.12 %
14.86 %
19.57 %
22.45 %
22.74 %
17.92 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
26.21 %
29.74 %
27.00 %
24.99 %
24.55 %
25.26 %
21.72 %
21.60 %
20.74 %
21.13 %
21.91 %
21.11 %
20.39 %
19.38 %
18.78 %
18.29 %
17.45 %
16.07 %
16.54 %
18.28 %
Others
30.26 %
25.36 %
28.19 %
28.69 %
29.49 %
29.73 %
32.03 %
32.15 %
32.49 %
31.82 %
29.39 %
30.07 %
27.51 %
8.39 %
7.84 %
8.49 %
8.27 %
7.50 %
21.89 %
10.89 %
No of Share Holders
0
1,93,871
2,61,165
2,39,520
2,16,385
2,10,785
2,14,539
2,16,055
2,02,329
1,90,894
2,01,054
2,07,055
1,90,691
1,82,142
1,79,870
2,02,198
1,77,554
1,69,802
1,69,700
1,65,542

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.9 1 1 1 1.5 1.5 1.5 1.5 1.5
Dividend Yield (%) 0.00 0.87 0.87 0.7 0.33 0.49 0.52 0.35 0.31 0.28

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Feb 2021 DIVIDEND Dividend
₹ 0.25 /share
 08 Feb 2021 355.30 331.95
30 Jul 2021 DIVIDEND Dividend
₹ 0.75 /share
 28 Jul 2021 364.15 371.45
06 Aug 2021 DIVIDEND Dividend
₹ 0.25 /share
 05 Aug 2021 377.45 386.30
25 Nov 2021 DIVIDEND Dividend
₹ 0.25 /share
 24 Nov 2021 317.10 312.65
18 Feb 2022 DIVIDEND Dividend
₹ 0.25 /share
 17 Feb 2022 312.00 305.70
21 Jul 2022 DIVIDEND Dividend
₹ 0.75 /share
 19 Jul 2022 250.75 308.10
03 Aug 2023 DIVIDEND Dividend
₹ 1.50 /share
 03 Aug 2023 292.80 317.15
30 Jul 2024 DIVIDEND Dividend
₹ 1.50 /share
 30 Jul 2024 399.75 564.40
06 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 06 Aug 2024 399.75 641.55
06 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Nov 2024 608.95 550.65
24 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Jan 2025 616.75 599.30
28 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 28 May 2025 447.80 528.85
31 Jul 2025 DIVIDEND Dividend
₹ 1.50 /share
 31 Jul 2025 528.85 491.95
07 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 07 Aug 2025 528.85 439.30
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Aug 2025 468.90 441.00
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2025 571.25 542.20

Announcements

Transcript Of The Earnings Conference Call For Q2 And The Half-Year Of FY26.4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome9 days ago
Announcement under Regulation 30 (LODR)-Change in Management10 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation10 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
Board Meeting Outcome for Outcome Of The Board Meeting10 days ago
Financial Results For The Quarter & Half Year Ended On September 30202510 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
UpdatesNov 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 31, 2025
Board Meeting Intimation for Inter-Alia To Consider And Approve The Unaudited Financial Results For The Second Quarter And Half-Year Ended On September 30 2025.Oct 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 29, 2025
UpdatesOct 29, 2025
Closure of Trading WindowSep 25, 2025
Announcement under Regulation 30 (LODR)-AllotmentSep 04, 2025
Transcript Of Earning Conference Call For Q1 Of FY26Aug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 07, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 04, 2025
UpdatesAug 01, 2025
Rumour verification - Regulation 30(11)Aug 01, 2025
Clarification sought from Granules India LtdAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJul 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 16, 2025
Reg. 34 (1) Annual Report.Jul 16, 2025
Board Meeting Intimation for Consideration And Approval Of Un-Audited Financial Results For The Quarter Ended On June 30 2025.Jul 14, 2025
UpdateJul 09, 2025
UpdateJun 28, 2025
Closure of Trading WindowJun 26, 2025
UpdateJun 20, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 17, 2025
Transcript Of Earnings Conference Call For Q4 Of FY25Jun 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 28, 2025
Record Date For Payment Of Final Dividend For FY25May 28, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025
Audited Financial Results For The Quarter And Financial Year Ended On March 31 2025May 28, 2025
Outcome Of The Board MeetingMay 28, 2025
Board Meeting Outcome for Outcome Of The Board MeetingMay 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 07, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Axis Large & Mid Cap Fund Direct-Growth
0.03%
-973879
-0.34%
-0.32%
Aditya Birla Sun Life Value Direct Fund-Growth
2.19%
-223662
-0.09%
-0.04%
Bandhan Balanced Advantage Fund Direct-Growth
0.00%
-195225
-0.45%
-0.62%
Axis Innovation Fund Direct-Growth
0.00%
-138549
-0.61%
-0.72%
Bandhan Business Cycle Fund Direct-Growth
0.83%
-35897
-0.03%
-0.08%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.40%
2732
0.02%
0.02%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.40%
2515
0.02%
0.02%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.40%
857
0.02%
0.02%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.40%
438
0.02%
0.02%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.04%
327
0.00%
0.00%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.21%
320
0.01%
0.00%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.40%
236
0.02%
0.02%
SBI Nifty 500 Index Fund Direct-Growth
0.04%
-187
0.00%
0.00%
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0.10%
-107
0.01%
0.01%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.40%
91
0.02%
0.02%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.10%
-86
0.01%
0.01%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.40%
-48
0.02%
0.02%
Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth
1.53%
-43
0.11%
0.32%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.40%
40
0.02%
0.02%
ICICI Prudential Nifty 500 Index Fund Direct-Growth
0.04%
37
0.00%
0.00%
Tata Nifty500 Multicap India Manufacturing 50:30:20 Index Fund Direct - Growth
0.38%
-30
0.02%
0.01%
Groww Nifty Total Market Index Fund Direct - Growth
0.04%
18
0.00%
0.00%
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth
1.53%
15
0.10%
0.32%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.04%
-10
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.61%
9
0.04%
0.07%

Technical Indicators

RSI(14)
Neutral
44.73
ATR(14)
Less Volatile
14.28
STOCH(9,6)
Neutral
57.30
STOCH RSI(14)
Neutral
36.02
MACD(12,26)
Bearish
-2.05
ADX(14)
Weak Trend
18.68
UO(9)
Bearish
49.09
ROC(12)
Downtrend And Accelerating
-4.14
WillR(14)
Neutral
-72.10
Bearish
5
Neutral
4
Bullish
0

About Granules

Granules India Limited is a vertically integrated pharmaceutical company founded in 1991. It manufactures Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company specializes in off-patent drugs and first-line defense products like Paracetamol, Ibuprofen, Metformin, and Guaifenesin. Granules India operates seven manufacturing facilities, six in India and one in the US, serving over 300 customers across 80 countries. The company has a strong focus on research and development, with a dedicated R&D center in Hyderabad. Granules India has expanded its operations through acquisitions, capacity enhancements, and the establishment of subsidiaries. It has received various regulatory approvals and certifications for its facilities and products. The company has filed numerous ANDAs, DMFs, and CEPs, and has launched several generic products in the US market.
Website
https://www.granulesindia.com
Chairperson NameC Krishna Prasad
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104